Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
First publishedAug 5, 14:34 UTC
Last updatedAug 5, 16:44 UTC · 15m ago
1 outlet
CNBC Top News
1 outlets over time — hover a bar for its window & outletslast updated
Answer
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
Reported by 1 outlet — CNBC Top News. See all sources ↓
Read the full report at CNBC Top News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
In brief
- What's the story?
- Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
- How widely is it covered?
- 1 outlet, average source rating 7.0/10.
- When was it last updated?
- 15m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Sources1TypeCoverage
Related in the knowledge graph
organizationAmericaorganizationBankorganizationCEOorganizationEmployersorganizationGLP-organizationOzempicorganizationWegovy
Sources (1)
Avg source rating 7.0/10Processing cluster
A1A2A3B1B2B3